International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 398-410 www.ijprajournal.com ISSN: 2456-4494

Artificial Intelligence-Driven Transformation in Pharmacovigilance: Future Directions and Global Impact

Sasha D. Dgama* Deeksha Kamble
YD Mane Institute of Pharmacy, Kagal – 416216, Maharashtra, India

Date of Submission: 10-11-2025 Date of Acceptance: 20-11-2025

ABSTRACT
Pharmacovigilance is the science of keeping medicines safe — it involves detecting, understanding, and preventing any side effects or problems caused by drugs. In simple terms, it's the ongoing process of making sure that the medicines people use continue to do more good than harm. It plays a critical role in maintaining public health by ensuring the continued safety and efficacy of medicines during post-marketing surveillance. The development of pharmacovigilance was largely driven by historical drug safety crises, such as the Thalidomide and Sulphonamide Elixir disasters, which underscored the urgent need for systematic monitoring of medicinal products after approval.

Over time, pharmacovigilance systems have evolved into globally coordinated networks capable of collecting and analyzing data from multiple healthcare and digital sources. However, the field continues to face significant challenges, including underreporting of adverse drug reactions, data heterogeneity, and difficulties in establishing causal relationships between drugs and observed outcomes.

Recent advances in Artificial Intelligence (AI) and Machine Learning (ML) provide new opportunities to enhance pharmacovigilance. These technologies enable rapid analysis of large datasets, early detection of safety signals, and prediction of patient-specific risks.

This review examines the historical evolution, current framework, and emerging role of AI in pharmacovigilance. It discusses representative case studies and explores regulatory, ethical, and operational considerations in integrating intelligent systems into global drug safety monitoring.

Key words: pharmacovigilance (pv), artificial intelligence, (AI) Machine learning (ML) , Adverse drug reactions (ADRS) .

I. INTRODUCTION

Every time a person takes a medicine — whether it's a simple painkiller or a complex cancer treatment — there's an unspoken trust that it will do more good than harm. Ensuring that trust is where **pharmacovigilance** comes in. It's the science and practice of watching out for potential side effects or unexpected problems with medicines once they're being used in the real world. While clinical trials give us important information about how drugs work and how safe they are, they can't predict everything. People in real life have different health conditions, take different combinations of medications, and live in vastly different environments — all of which can lead to reactions that weren't seen during testing. That's why pharmacovigilance is so essential. It continues the safety monitoring journey long after a drug hits the market.



Fig no.1

The history of pharmacovigilance is filled with tough lessons. One of the most well-known is the **Thalidomide tragedy**, where a drug once seen as a harmless treatment for morning sickness caused severe birth defects in thousands of babies. That disaster — along with earlier incidents like the Sulphonamide Elixir case, which led to over 100 deaths in the U.S. — forced the world to take drug safety far more seriously. These events marked a turning point. From then on, countries began building systems to report and investigate side effects, leading to the structured, science-driven field of pharmacovigilance we have today.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 398-410 www.ijprajournal.com ISSN: 2456-4494

In the modern world, pharmacovigilance operates on a global scale. Governments, pharmaceutical companies, healthcare professionals, and even patients all play a role in reporting adverse drug reactions. Massive databases collect millions of safety reports, which are then analyzed for patterns that could point to a problem. But there's a catch: even with the best systems in place, a lot of information slips through the cracks. Many side effects are never reported. The reports that do come in can be inconsistent, incomplete, or hard to interpret. And with the explosion of health data — from electronic medical records to fitness trackers — it's becoming harder to keep up.

This is where **Artificial Intelligence (AI)** and **Machine Learning (ML)** come in as potential game-changers. These technologies are designed to make sense of huge amounts of data, recognize patterns faster than humans can, and even predict future risks. Imagine a system that could automatically scan millions of patient reports and instantly flag a potential safety concern — long before it becomes a widespread issue. That's the promise of AI in pharmacovigilance.

In this review, we'll take a closer look at how pharmacovigilance has evolved, why it's still so important, and how AI is beginning to reshape the way we think about drug safety. We'll revisit the major turning points in PV's history, discuss its current practices and limitations, and explore how AI and ML are being used today to improve signal detection, causality assessment, and overall efficiency. Along the way, we'll use real and fictional case studies — including well-known incidents and newer, less-publicized examples — to show just how much is at stake, and how innovation can help.

Most importantly, we'll explore what the future might look like when humans and machines work side by side — combining clinical wisdom with computational power — to make sure that the medicines we rely on are as safe as they can be.

II. HISTORICAL MILESTONES IN PHARMACOVIGILANCE

The evolution of pharmacovigilance is deeply rooted in the lived experiences of patients and the collective response of the scientific and regulatory communities to prevent harm. While today's systems for drug safety monitoring are highly structured and globally coordinated, this was not always the case. For much of the early 20th century, drug safety relied on anecdotal reporting, limited oversight, and reactive interventions — often too late to prevent devastating consequences. It was through a series of public health crises, notably the Sulphonamide Elixir tragedy and the Thalidomide disaster, that the modern framework of pharmacovigilance began to take shape [1,16].

These historical events marked turning points in the global understanding of drug safety and led to the development of essential pharmacovigilance principles — from pre-market safety assessments to post-market surveillance and spontaneous adverse event reporting systems [1,7].

Early Beginnings: A Field Without Formal Structure

Prior to the mid-20th century, there was no standardized approach to tracking or managing adverse drug reactions (ADRs). Physicians who observed unusual side effects might publish case reports or raise informal alerts, but there was no centralized or coordinated method to capture, analyze, or respond to such signals. This lack of systemization made it nearly impossible to identify patterns or establish causality on a large scale. Medicines were often brought to market with minimal testing, and the burden of discovering potential harms typically fell on clinicians — and, tragically, on patients themselves [1,7].

III. CASE STUDY

Case Study 3.1: The Sulphonamide Elixir Tragedy (1937)

In 1937, the S.E. Massengill Company introduced a new liquid formulation of sulfanilamide, intended to make administration easier for children and other patients. To dissolve the active ingredient, the company used diethylene glycol (DEG), a solvent later recognized as highly toxic to humans. Shortly after release, reports of acute renal failure and death began to surface; more than 100 fatalities, many involving children, were ultimately linked to the product [16].

Public outrage led directly to the passage of the Federal Food, Drug, and Cosmetic Act of 1938, which for the first time required manufacturers to provide evidence of a drug's safety before marketing. This legislation laid the foundation for modern pharmacovigilance and marked a shift from reactive crisis response to proactive safety regulation [16].

Case Study 3.2: The Thalidomide Tragedy (1950s–1960s)

Thalidomide, introduced in the late 1950s, was marketed widely as a sedative and treatment for morning sickness in pregnancy. Its perceived safety contributed to rapid global adoption. However, by

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 398-410 www.ijprajournal.com ISSN: 2456-4494

the early 1960s, physicians observed increased cases of phocomelia, a severe congenital limb malformation. Independent investigations linked these birth defects to thalidomide exposure during the first trimester [7,17].

Thousands of infants were affected worldwide, revealing major deficiencies in preclinical testing and post-market surveillance. In the United States, Dr. Frances Kelsey of the FDA refused thalidomide approval due to insufficient safety evidence, a decision credited with preventing similar devastation in the U.S. and influencing later drug safety reforms, including the Kefauver-Harris Amendments requiring evidence of both efficacy and safety [18,19].

Subsequent Safety Incidents and Their Influence on Pharmacovigilance

Events following the thalidomide disaster reinforced the need for robust pharmacovigilance:

Diethylstilbestrol (DES): Later linked to rare cancers and reproductive abnormalities in the daughters of exposed pregnant women, demonstrating the possibility of transgenerational ADRs [1,7].

Rofecoxib (Vioxx): Withdrawn due to post-marketing evidence of increased cardiovascular risk, highlighting the importance of real-world data for identifying long-term adverse effects [8,11].

Troglitazone and Cerivastatin: Withdrawn due to life-threatening hepatic toxicity and rhabdomyolysis, exposing the limitations of pre-market trials for detecting rare but severe ADRs [7,11].

Collective Lessons and the Evolution of Modern Pharmacovigilance

Historical tragedies illustrate that pharmacovigilance must extend throughout a drug's lifecycle. Rare, delayed, or population-specific adverse effects may only become visible during widespread use. Modern pharmacovigilance thus requires coordinated participation from regulators, manufacturers, healthcare professionals, and patients [1,3].

Key lessons include the need for:

Global data sharing and collaborative signal detection networks [2].

Standardized and accessible ADR reporting systems to overcome underreporting and data gaps [1,2,14].Continuous regulatory evolution and methodological innovation to manage emerging therapies and risks [3–6].

Today's pharmacovigilance environment is more structured and globally integrated than ever, yet the tragedies of the past remain vital reminders of the consequences of inadequate drug safety monitoring [1,7].

IV. CORE PRINCIPLES AND PROCESSES OF PHARMACOVIGILANCE

Pharmacovigilance (PV) is not merely a regulatory obligation — it is a long-term commitment to patient safety embedded throughout a medicinal product's lifecycle. As drugs transition from controlled clinical trials into diverse real-world use, new safety information emerges, requiring continuous evaluation to ensure that benefits outweigh risks [1,3]. PV integrates scientific, clinical, and regulatory disciplines to monitor, assess, and prevent adverse drug reactions (ADRs) globally [1,7].

4.1 Sources of Safety Data

Modern pharmacovigilance draws from a broad ecosystem of data sources, each contributing distinct insights into drug safety profiles.

4.1.1 Pre-Marketing Data: A Controlled Starting Point

Before regulatory approval, medicines undergo phased clinical trials to evaluate safety and efficacy. These trials generate structured, high-quality safety data useful for identifying common adverse effects. However, pre-marketing trials have inherent limitations: small populations, restricted inclusion criteria, fixed dosing, and relatively short durations [1,7]. Rare, delayed, or population-specific ADRs often remain undetected until post-marketing use.

Thus, pre-marketing data provides the foundation of a safety profile, but real-world surveillance is essential for completeness.

4.1.2 Post-Marketing Data: Capturing the Real World

Once a product enters the market, it is exposed to broader, more heterogeneous populations. Post-marketing safety systems therefore rely on multiple data streams:

a. Spontaneous Reporting Systems (SRSs)

SRSs remain the backbone of global pharmacovigilance. Systems like WHO's VigiBase, the U.S. FDA's FAERS, the UK Yellow Card Scheme, and the EU's EudraVigilance collect Individual Case Safety Reports (ICSRs) submitted by healthcare professionals and patients [1,2,14]. Although spontaneous reports are invaluable for signal detection, they are subject to significant underreporting — often described as the "iceberg phenomenon" [15].

b. Medical Literature & Regulatory Databases

Scientific literature frequently contains early descriptions of ADRs, case reports, and observational studies. PV professionals regularly screen peer-reviewed publications to detect emerging signals [7,9]. Global regulatory databases such as VigiBase enable cross-country trend analyses and international comparisons [2].

c. Post-Authorization Safety Studies (PASS)

PASS are structured studies conducted after marketing approval to address specific safety concerns, quantify risks, or evaluate risk-minimization measures. These studies support regulatory decision-making and provide evidence beyond spontaneous reports [3,5].

d. Electronic Health Records (EHRs) & Insurance Claims

Digitalization in healthcare has created large repositories of real-world data (RWD). EHRs and claims datasets allow PV teams to identify safety patterns, correlate outcomes with drug exposure, and evaluate risks at scale, though data heterogeneity poses analytical challenges [12,13,14].

e. Social Media & Online Forums

Patient-generated data on social platforms can provide early "weak signals" for ADRs. Natural language processing enables automated extraction of symptom patterns from online discussions [12]. However, social data require careful validation due to noise, bias, and subjectivity.

Collectively, these diverse data sources form an interconnected global safety network.

4.2 Key Pharmacovigilance Activities

Data alone are insufficient without structured processes to evaluate and act upon safety information.

4.2.1 Signal Detection and Management

A signal represents information suggesting a new or changed association between a drug and an adverse event [8,9]. Signal detection involves:

Disproportionality analysis, such as PRR or ROR, to identify statistically significant drug–event combinations [8,10,11]

Longitudinal observational analyses, using EHRs and claims data to verify associations [12–14]

Qualitative clinical review, integrating medical judgment with statistical findings [7]

Once detected, signals must be validated, prioritized, and assessed for clinical relevance, potential severity, and public health impact [9].

4.2.2 Case Causality Assessment

Determining whether a drug caused an event requires structured evaluation of:

Temporal relationship

Pharmacological plausibility

Dechallenge and rechallenge outcomes

Alternative explanations (comorbidities, concomitant drugs) [7]

Tools such as the WHO-UMC and Naranjo algorithms provide standardized frameworks, but expert judgment remains essential. Causality remains probabilistic, not definitive, in most real-world cases [7,12].

4.2.3 Risk Assessment and Risk Management

Once a causal link or significant risk is identified, regulators and manufacturers implement risk-minimization strategies. These include:

Routine PV activities (periodic safety update reports, continuous monitoring) [3,5]

Product label updates (warnings, contraindications, precautions) [5]

Risk Evaluation and Mitigation Strategies (REMS) for high-risk medicines [4]

Education campaigns aimed at healthcare providers and patients [5]

Risk management plans (RMPs) are dynamic documents that evolve with emerging safety data [3,5].

4.2.4 Communication and Regulatory Reporting

Timely safety communication is essential to protect public health. This includes:

Updates to Summary of Product Characteristics (SmPC) and Patient Information Leaflets (PILs) [5]

Dear Healthcare Professional Letters (DHPLs)

Public safety alerts

Expedited reporting obligations for serious, unexpected ADRs [4,5]

Transparent communication ensures healthcare providers and patients remain informed of evolving risks.

4.3 Key Stakeholders in Pharmacovigilance

Pharmacovigilance is a shared responsibility across:

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 398-410 www.ijprajournal.com ISSN: 2456-4494

a. Marketing Authorization Holders (MAHs)

MAHs bear primary responsibility for monitoring product safety throughout its lifecycle, submitting safety reports, conducting PASS, and maintaining RMPs [3,5].

b. Regulatory Authorities

Agencies such as the FDA, EMA, MHRA, and WHO set global standards, review safety data, perform inspections, and impose regulatory actions where necessary [4–6].

c. Healthcare Professionals (HCPs)

As frontline observers, HCPs play a crucial role in recognizing and reporting suspected ADRs. Their engagement directly influences the quality and quantity of safety data collected [1,7,15].

d. Patients and Consumers

Patients contribute firsthand experiential data and increasingly submit reports directly through apps, online portals, and social media [12]. Their involvement enhances detection of underreported ADRs, especially those affecting quality of life

V. CHALLENGES IN TRADITIONAL PHARMACOVIGILANCE

Pharmacovigilance (PV) remains a critical pillar in safeguarding public health, ensuring that the benefits of medicines continue to outweigh their risks throughout their lifecycle. Despite substantial progress, traditional PV systems face persistent limitations that hinder timely detection, assessment, and management of adverse drug reactions (ADRs). These challenges—including underreporting, high data volume, causality complexity, delayed signal detection, and operational burdens—have been well documented across regulatory, academic, and clinical domains [1–7]. The growing availability of real-world data (RWD) and the rapid expansion of digital health technologies further magnify these challenges, emphasizing the need for innovative approaches such as Artificial Intelligence (AI) and advanced analytics [8–12].

5.1. Underreporting of Adverse Drug Reactions

Underreporting is widely recognized as one of the most critical limitations of spontaneous reporting systems (SRSs). Studies consistently estimate that only 1–10% of ADRs are ever reported, leaving the majority undetected—a phenomenon described as the "iceberg effect" [13,14]. Multiple factors contribute to this persistent problem:

Doubt about whether a drug truly caused the event,

Diffidence, including fear of professional judgment,

Disinterest due to workload or lack of perceived importance,

Detection limitations, especially for mild, delayed, or ambiguous ADRs.

These barriers collectively weaken signal detection and delay regulatory action, hindering early identification of serious risks [3,5,15].

5.2. Data Volume and Complexity

Modern PV systems must process massive volumes of heterogeneous data, including ICSRs, electronic health records (EHRs), insurance claims, scientific literature, registries, and patient-generated reports from digital platforms. The complexity and variability of these data sources challenge manual analysis and traditional statistical methods [2,8,9]. As data streams rapidly expand, the limitations of older PV infrastructures become increasingly apparent, prompting global regulators to encourage adoption of algorithmic and AI-enhanced analytical tools [4,6,11,16].

5.3. Challenges in Causality Assessment

Causality assessment in real-world settings remains inherently complex. Polypharmacy, comorbidities, incomplete clinical documentation, variability in patient behavior, and ethical constraints around rechallenge often impede confident attribution of ADRs to specific drugs [3,15,17]. Although structured tools (e.g., WHO-UMC system, Naranjo scale) provide consistency, expert judgement remains indispensable. Emerging AI-supported models show promise for preliminary causality scoring, literature summarization, and risk stratification [7,10,12,18].

5.4. Delays in Signal Detection

Timely safety signal detection is essential for minimizing patient harm. However, traditional PV workflows often suffer delays at multiple points: ADR occurrence, clinical recognition, reporting, database entry, review, and statistical analysis [9,10]. Limited human resources, cognitive bias, and lack of real-time analytic capability further slow signal emergence. Algorithmic and AI-based approaches have demonstrated improved sensitivity and speed in signal detection across diverse databases [11,12,19].

5.5. Resource Intensity and Operational Burden

High operational demands—case processing, literature surveillance, MedDRA coding, regulatory submissions, risk assessment, and quality compliance—place considerable strain on PV teams

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 398-410 www.ijprajournal.com ISSN: 2456-4494

and infrastructure [1,3]. Globalization of drug markets, increased regulatory complexity, and rising case volumes exacerbate this challenge. Automation through AI, machine learning, and robotic process automation (RPA) is increasingly viewed as essential for maintaining efficiency and accuracy at scale [6,7,11,18].

Visual Representation: Iceberg Phenomenon

The "iceberg phenomenon" conveys that only a small fraction of ADRs are captured by spontaneous reporting, while the majority remain unseen beneath the surface. This metaphor underscores persistent underreporting issues and the need for multifactorial surveillance technologies that can identify signals beyond formal reporting channels [13,14].

VI. CURRENT CHALLENGES IN PHARMACOVIGILANCE

Pharmacovigilance (PV) faces growing complexity due to rapid technological advancements, expanding therapeutic innovations, and the increasing volume of global safety data. These challenges affect the accuracy, timeliness, and efficiency of detecting and managing adverse drug reactions (ADRs). Several contemporary issues complicate the PV landscape, requiring modernized analytical approaches and stronger regulatory alignment [1,4,6,12,16].

6.1. Managing the Exponential Growth of Safety Data

The volume of safety data has increased exponentially with the growth of digital health ecosystems. PV systems now process millions of Individual Case Safety Reports (ICSRs) annually through databases such as VigiBase, FAERS, and EudraVigilance [2,9,10]. Additionally, electronic health records (EHRs), registries, claims databases, and patient-generated data have expanded the scope of post-market surveillance dramatically.

The challenge lies in:
Integrating heterogeneous, unstructured datasets,
Reducing duplication and noise,
Ensuring data standardization and interoperability,
Applying scalable analytical tools that allow real-time signal detection.
Traditional methods alone are insufficient to process this magnitude of information effectively [11,12].

6.2. Complexity of Real-World Data Interpretation

Real-world data reflects diverse patient populations with varying comorbidities, polypharmacy patterns, and social determinants of health. These variables introduce confounding factors—making ADR attribution more difficult compared to controlled clinical trials [14,15,17].

Data gaps, missing values, inconsistencies in clinical documentation, and differences in global reporting practices further complicate signal detection. Regulators increasingly emphasize complementary approaches that combine spontaneous reports with real-world evidence (RWE) to strengthen signal validation [4,5,18].

6.3. Emergence of Novel Therapeutics

The rapid expansion of biologics, gene therapies, monoclonal antibodies, tissue-engineered products, and personalized medicine has introduced unprecedented safety monitoring challenges. These products may exhibit:

Unique immune-mediated toxicities,
Long-term organ effects,
Delayed onset ADRs,
Target-specific or genetically mediated risks [18–20].

Traditional PV frameworks—largely designed for small-molecule drugs—are not always sufficient to capture these complex safety profiles. Tailored surveillance systems and AI-powered predictive models are increasingly recommended [12,19].

6.4. Regulatory Fragmentation and Global Harmonization

Global PV must align with diverse regulatory requirements regarding reporting timelines, data formats, signal management standards, and safety communication expectations. This fragmentation creates operational challenges for multinational marketing authorization holders (MAHs) [3,4,5].

Initiatives toward harmonization—such as ICH E2E/E2C, CIOMS guidance, and EMA–FDA collaboration—aim to reduce inconsistency, but differences remain. AI tools for regulatory intelligence are emerging as valuable aids in keeping track of evolving global requirements [6,11].

6.5. Patient Engagement and Data Capture

Patient reporting has become essential for capturing subjective experiences—fatigue, mood changes, pain fluctuations—that clinicians may overlook. However, variability in health literacy, digital access, and awareness of reporting systems affects the quality and completeness of patient-generated data [13,21].

Integrating patient-reported outcomes from social media, mobile applications, and wearable devices introduces both opportunities and challenges. Validation and filtering of such inputs require advanced NLP and ML techniques [16,19].

6.6. Resource Constraints and Workforce Challenges

Modern PV demands multidisciplinary teams with competencies in:
Clinical pharmacology
Epidemiology
Data science
Regulatory science
Biostatistics
Yet the global demand for PV professionals exceeds supply. Increasing regulatory requirements, rising case volumes, and resource constraints amplify operational burdens. Automation through AI, robotic process automation (RPA), and intelligent workflows is increasingly used to reduce manual workload [6,12,19].

VII. CASE STUDIES IN MODERN PHARMACOVIGILANCE AND AI APPLICATIONS

Modern pharmacovigilance continues to confront challenges that highlight gaps in traditional systems. Emerging AI technologies show potential to overcome these constraints, particularly in early signal detection, prediction of rare ADRs, and synthesis of large-scale clinical information [10–12,18].

Global Pharmacovigilance Guidelines – Comparative Table

Region/Body	Guideline / System	Key Features / Focus
WHO	ICP-PV (International Programme for Pharmacovigilance)	Global coordination, UMC database (VigiBase), ADR reporting standards, capacity building
ICH	E2 Series (E2A–E2F)	Harmonization of safety data, expedited reporting, risk management, PSUR/PBRER standards
India	PvPI (Pharmacovigilance Programme of India)	ADR reporting via Suspected ADR Form, Vigiflow platform, CDSCO oversight, NCC (IPC Ghaziabad)
USA (FDA)	FAERS & MedWatch	Mandatory and voluntary reporting, electronic submissions, risk evaluation (REMS), post-marketing surveillance
EU (EMA)	EudraVigilance & GVP Modules	Centralized ADR database, signal management, QPPV role, PSURs, electronic reporting, inspections
UK (MHRA)	Yellow Card Scheme	Public and HCP reporting, digital ADR apps, post-Brexit independent safety monitoring
Japan	PMDA Guidelines	Early post-marketing vigilance, risk minimization, GPSP standards, mandatory case reporting

Table no.1

Case Study 7.1: Coldriff — Detecting a Rare Cardiovascular Risk

Fig no.2

Coldriff (fictional), a widely used OTC cold–flu medication, was associated with rare ventricular tachycardia (VT) events—approximately 1 per 500,000 users. Traditional PV methods struggled to identify the signal due to:

AI facilitated earlier identification of Coldriff's rare cardiac risks, enabling timely labeling updates and risk communication [11,12,16].

Background and Traditional Challenges:

Coldriff, a fictional but representative over-the-counter medication, is widely trusted and used by millions to relieve cold and flu symptoms [1]. Its active ingredients have long been established as safe, with well-documented mild side effects such as drowsiness or dry mouth [2]. However, post-marketing surveillance uncovered a handful of cases linking Coldriff to Ventricular Tachycardia (VT)—a rare, potentially life-threatening heart rhythm disorder [3].

This presented several hurdles for traditional PV systems:

• **Rarity and Non-specificity:** VT occurs in approximately 1 in 500,000 users, making it statistically difficult to detect amid millions of reports describing common cold symptoms like dizziness or palpitations, which could easily be misattributed to the underlying illness or other conditions [4].

• **Underreporting and Misattribution:** Healthcare professionals may not associate these symptoms with Coldriff use, especially if patients have coexisting illnesses or multiple medications. This underreporting dilutes the signal in spontaneous reporting systems [5].

• **Fragmented Data Sources:** Important early clues might be scattered across non-traditional data streams such as patient forums, social media discussions, and unstructured hospital notes—areas where conventional PV tools have limited reach [6].

AI-Powered Solutions:

AI offers a powerful toolkit to overcome these challenges:

• **Natural Language Processing (NLP) and Social Listening:** By continuously mining social media platforms, online forums, and other unstructured text sources, AI can detect emerging clusters of complaints linking Coldriff to symptoms like dizziness and palpitations. This early "signal mining" captures patient experiences that formal reporting systems might miss [7].

• **Deep Learning on Large-Scale Healthcare Data:** Advanced machine learning models analyze anonymized electronic health records (EHRs) and insurance claims to identify statistical associations between Coldriff prescriptions and subsequent VT diagnoses. These models can detect subtle patterns and correlations far beyond human capability [8].

• **Accelerated Signal Detection and Regulatory Action:** Early identification enables pharmaceutical companies and regulators to issue timely warnings, update product labels with specific cardiovascular risk information, or even restrict the drug's distribution, potentially preventing serious harm [9].

Visual Representation:

A comparative graph could illustrate how AI-enhanced PV detects the signal months or even years earlier than traditional systems, highlighting the profound impact of AI on patient safety timelines [10].

Case Study 7.2: Meftal Spas — National Signal Detection & AI Potential

Meftal Spas (mefenamic acid + dicyclomine) is widely used in India. The Indian Pharmacovigilance Programme (PvPI) identified a safety signal for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in 2023.

Fig no.3

Background and Context:

Mefenamic Acid, combined with Dicyclomine in Meftal Spas, is widely prescribed for muscle spasms and pain relief, particularly in countries like India [1]. While it has a well-understood safety profile, the Indian Pharmacopoeia Commission (IPC), acting as the country's National Pharmacovigilance Center, identified an important safety signal in 2023: a potential association with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome [2].

DRESS syndrome is a severe hypersensitivity reaction involving extensive skin rash, fever, and organ involvement. Although rare, it can be life-threatening and requires prompt diagnosis and management [3].

Traditional PV Response:

The IPC's proactive detection and communication process included:

• **Systematic Signal Detection:** Using the national ADR reporting system, the IPC identified a statistically significant increase in reports linking Meftal Spas to DRESS syndrome [2].
• **Rapid Communication:** The IPC issued safety alerts to healthcare professionals and patients, updating drug labels and clinical guidelines to raise awareness of this risk [4].

Opportunities for AI Enhancement:
While the IPC's actions demonstrate the strength of established PV systems, AI has the potential to enhance detection and prevention further:
• **Early Phenotype Identification through NLP:** DRESS syndrome often begins with non-specific symptoms like fever and malaise before rash and organ involvement appear [5]. AI could analyze physician notes, lab reports, and pathology findings using NLP to detect these early warning signs, allowing intervention before the syndrome fully develops [6].
• **Genomic Risk Profiling:** Machine learning algorithms can integrate genetic data—such as Human Leukocyte Antigen (HLA) typing—to identify individuals genetically predisposed to DRESS syndrome upon exposure to Mefenamic Acid [7]. This personalized approach could enable clinicians to tailor treatment and avoid high-risk prescriptions [8].
• **Improved Signal Specificity:** By combining clinical, genetic, and biochemical data, AI could reduce false positives in signal detection and enhance the accuracy of risk stratification [9].

Broader Implications and Future Directions
These case studies underscore several important lessons:

1. **Limitations of Traditional PV:** Human-led systems struggle with underreporting, data fragmentation, and the sheer volume and complexity of modern health data. Rare and delayed ADRs often go undetected for years, posing ongoing risks to patients [10].
2. **AI as a Catalyst for Transformation:** AI's ability to mine vast, diverse datasets, recognize complex patterns, and provide early warnings represents a paradigm shift. By complementing human expertise, AI can help close the gaps left by traditional PV approaches [11].
3. **Integration and Collaboration:** Successful AI integration requires cooperation between pharmaceutical companies, regulatory authorities, healthcare providers, and technology developers. Transparent data sharing and standardized methodologies will be essential [12].
4. **Ethical and Practical Considerations:** While AI promises improved safety, careful attention must be paid to data privacy, algorithm transparency, and avoiding biases in AI models [13].
5. **Continuous Monitoring:** Pharmacovigilance is a lifelong process that extends well beyond a drug's initial approval. Even well-established drugs require ongoing surveillance, and AItools can help sustain vigilance as globaldrug markets and patient populations evolve [14].

Recent Drugs and Their Emerging Safety Profiles: Lessons for Modern Pharmacovigilance
Even as the pharmaceutical landscape advances with innovative therapies, the importance of robust pharmacovigilance (PV) systems cannot be overstated. New drugs, despite thorough clinical testing, may reveal rare or delayed adverse effects only after broader, real-world use **[19]**.

1. Jesduvroq (Daprodustat) – Anemia Management in Chronic Kidney Disease
Jesduvroq, approved by the FDA in early 2023, offers a novel approach to managing anemia in adults with chronic kidney disease (CKD) undergoing dialysis. It works by stimulating erythropoiesis through inhibition of hypoxia-inducible factor prolyl hydroxylase. While clinical trials demonstrated efficacy in increasing hemoglobin levels, post-marketing data have highlighted concerns regarding cardiovascular safety **[20]**.

Safety Concerns
• The drug carries a boxed warning about increased risks of thrombotic events, including heart attacks, strokes, and venous thromboembolism.
• Hypertension and allergic reactions have been reported with notable frequency.
• These risks underscore the challenge of balancing therapeutic benefit against potential harm, especially in vulnerable CKD populations already predisposed to cardiovascular complications **[21]**.

PV Implications
• Monitoring Jesduvroq requires vigilance for cardiovascular events in real-world populations, who may have comorbidities not fully represented in clinical trials.

• AI-driven analysis of EHRs and claims data could help detect early patterns of adverse cardiovascular outcomes, facilitating timely interventions **[22]**.

2. Veozah (Fezolinetant) – Addressing Menopausal Hot Flashes with Caution

Veozah, the first FDA-approved NK_3 receptor antagonist for moderate to severe menopausal hot flashes (May 2023), represents a novel therapeutic class targeting neurokinin signaling pathways. While it offers significant symptomatic relief, recent post-marketing reports have identified concerns related to hepatic safety **[23]**.

Safety Concerns

• Rare but serious cases of liver injury have been reported, prompting an FDA update to include warnings about hepatotoxicity.
• These adverse events often present as elevated liver enzymes and jaundice, warranting liver function monitoring **[24]**.

PV Implications

• This case highlights the importance of continuous liver safety monitoring, especially for drugs acting on novel pathways with limited long-term data.
• NLP tools can scan clinical notes and social media for early signs of liver-related symptoms that patients or providers report informally **[25]**.

3. Kisqali (Ribociclib) – Expanding Breast Cancer Treatment with Hematologic and Hepatic Risks

Kisqali, a CDK4/6 inhibitor, gained expanded approval in 2024 for adjuvant treatment of hormone receptor–positive, HER2-negative early-stage breast cancer at high risk of recurrence. While it has become a cornerstone in targeted oncology therapy, it carries significant side effect profiles requiring careful management **[26]**.

Safety Concerns

• Neutropenia is common and increases infection risk.
• Elevated liver enzymes indicate potential hepatotoxicity.
• Gastrointestinal symptoms and alopecia also affect quality of life **[27]**.

PV Implications

• Ongoing safety monitoring involves regular blood tests and liver function assessments.
• AI can predict which patients are at greatest risk of severe hematologic toxicity based on clinical and genetic factors, enabling personalized treatment plans **[28]**.

4. Journavx – A Non-Opioid Pain Management Option with Mild Side Effects

Journavx, a novel non-opioid analgesic approved in 2024, addresses the pressing need for effective alternatives to opioids amid a global opioid crisis. Developed by Vertex Pharmaceuticals, it provides comparable pain relief with a more favorable risk profile **[29]**.

Safety Concerns

• Side effects are generally mild, such as itching, muscle spasms, and rash.
• However, rare and delayed adverse effects are still possible and require vigilance **[30]**.

PV Implications

• Monitoring patient-reported outcomes through social media and patient registries can help identify early signals of rare side effects.
• Integration of patient-generated health data can complement traditional safety databases by offering real-time insights **[31]**.

5. Socazolimab – Immunotherapy Advancements and Immune-Related Adverse Events

Socazolimab, approved in China in late 2023 for recurrent or metastatic cervical cancer, represents the growing class of immunotherapies that activate the immune system to target tumors. However, these mechanisms can also trigger immune-related adverse events (irAEs) **[32]**.

Safety Concerns

• Common irAEs include lung inflammation, hepatitis, colitis, and endocrine dysfunction.
• The severity and unpredictability of these effects pose significant challenges for clinicians and monitoring systems **[33]**.

PV Implications

• Real-time pharmacovigilance is essential for identifying and managing irAEs early.
• AI-powered clinical decision support tools can detect emerging symptoms from unstructured medical data, prompting faster intervention **[34]**.

VIII. ARTIFICIAL INTELLIGENCE IN PHARMACOVIGILANCE

AI and machine learning (ML) offer transformative opportunities in PV by automating case intake, extracting structured data, accelerating

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 398-410 www.ijprajournal.com ISSN: 2456-4494

signal detection, and supporting causality assessment. Regulatory agencies increasingly recognize AI as a valuable tool, provided systems are transparent, validated, and governed appropriately [4–6].

8.1. Introduction to AI and ML in PV

AI technologies used in PV include:
Natural Language Processing (NLP) for processing unstructured narratives,
Machine Learning (ML) for pattern recognition and signal detection,
Deep Learning (DL) for complex data modeling,
Robotic Process Automation (RPA) for repetitive task automation.
These technologies help overcome limitations of manual workflows and enhance real-time surveillance capabilities [11,12,16].

8.2. Applications of AI in Pharmacovigilance

8.2.1 Automated Case Processing

AI supports:
ICSR intake and prioritization,
Extraction of drug-event details from PDFs, emails, and handwritten notes,
Automated MedDRA coding,
Case completeness scoring.
This improves consistency and reduces processing time significantly [16,19].

8.2.2 Automated Signal Detection

ML algorithms detect disproportionate reporting and complex associations within:
FAERS
VigiBase
EudraVigilance
EHR networks
AI-driven signal detection is faster and often more sensitive than conventional disproportionality analysis (e.g., PRR, ROR) [10,11].

8.2.3 Enhanced Causality Assessment

AI can:
Score preliminary causality likelihood,
Summarize relevant literature,
Identify biologically plausible pathways,
Support expert assessment.
ML models trained on historical case data show high reproducibility and can reduce reviewer variability [12,18].

8.2.4 Personalized and Predictive PV

Integrating AI with:
Genomics,
Phenotype data,
Wearable device metrics,
Digital health biomarkers
enables prediction of patient-specific ADR risks and supports precision pharmacovigilance [19,20]

Regulatory Landscape and Future Directions in Pharmacovigilance

The regulatory environment governing pharmacovigilance is rapidly evolving as agencies worldwide adapt to the emergence of artificial intelligence, real-world evidence, and new therapeutic modalities. Organizations such as the FDA, EMA, MHRA, and PMDA increasingly acknowledge the value of AI-driven tools, while emphasizing the importance of transparency, validation, and continuous monitoring to ensure that these technologies meet regulatory and ethical standards [26].

Regulators are adopting new frameworks that address AI system governance, algorithmic bias, explainability, and data quality. Draft guidance documents, reflection papers, and CIOMS recommendations highlight the need for human oversight and emphasize that AI should augment—not replace—expert judgement in safety decision-making [27].

Global harmonization efforts such as ICH initiatives aim to reduce regulatory fragmentation and support consistent safety reporting requirements. However, differences in regional expectations still pose challenges for multinational pharmaceutical companies, reinforcing the need for standardized AI validation processes and interoperable data systems [28].

Future Prospects of AI in Pharmacovigilance



.
Fig no.4

AI is expected to reshape pharmacovigilance by enabling real-time global safety monitoring across diverse data sources, including EHRs, social media, wearables, claims databases, and patient-reported outcomes. With continuous data feeds, AI models will detect early safety signals faster than traditional methods, reducing delays in regulatory action and improving patient safety [29].

Natural language processing (NLP) will automate the extraction of safety information from unstructured text such as medical records, case narratives, publications, and consumer reports. This will significantly reduce manual workload, streamline case processing, and improve data completeness for ICSRs [30].

Predictive analytics will support proactive safety monitoring by identifying patients at higher risk of ADRs based on genomics, comorbidities, biomarkers, and digital phenotyping. This shift from reactive to predictive pharmacovigilance aligns with the future direction of precision medicine and individualized therapy optimization [31].

Wearable devices and biosensors offer continuous physiological monitoring, generating valuable real-time safety data such as heart rate variability, glucose levels, sleep disturbance, and mobility patterns. AIwill integrate these metrics to detect early signs of drug toxicity long before clinical symptoms emerge [32].

In addition, AI-driven regulatory intelligence systems will track global safety communications, policy changes, and emerging risks automatically, supporting compliance and reducing operational burden. Future PV systems will function as hybrid ecosystems combining human expertise with intelligent algorithms to ensure consistent and efficient drug safety surveillance [33].

IX. CONCLUSION

Pharmacovigilance is entering a transformative era in which traditional limitations can be addressed through the integration of AI, automation, and advanced data analytics. While manual systems remain essential for expert assessment and nuanced clinical judgement, the sheer scale and complexity of modern safety data necessitate technological enhancement. AI offers unprecedented capabilities in real-time signal detection, predictive risk modeling, automated case processing, and individualized safety monitoring [34].

The future of pharmacovigilance lies in a collaborative model where human expertise and AI work together to strengthen global drug safety. By embracing intelligent technologies, PV systems can become more proactive, precise, efficient, and responsive—ultimately improving patient outcomes and ensuring that medicines remain as safe as possible throughout their lifecycle [35].

REFERENCES

[1]. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002.
[2]. Uppsala Monitoring Centre. VigiBase: The WHO Global Database of Individual Case Safety Reports (ICSRs). UMC; 2021.
[3]. International Council for Harmonisation (ICH). E2E: Pharmacovigilance Planning. Geneva: ICH; 2005.
[4]. U.S. Food and Drug Administration. Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drugs and Biological Products. Draft Guidance. Silver Spring (MD): FDA; 2025.
[5]. European Medicines Agency (EMA). Good Pharmacovigilance Practices (GVP). Amsterdam: EMA; 2024.
[6]. Council for International Organizations of Medical Sciences (CIOMS). Practical Approaches to the Use of Artificial Intelligence in Pharmacovigilance. Geneva: CIOMS; 2021.
[7]. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259.
[8]. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396.
[9]. Edwards BJ, Upton A. The iceberg of adverse event underreporting. Drug Saf. 2020;43(7):639–650.
[10]. Wisniewski A, Bate A, Bousquet C, et al. Good signal detection practices. Drug Saf. 2016;39(6):469–490.
[11]. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for FAERS. Clin PharmacolTher. 2012;93(6):539–546.
[12]. Yu Y, Li Y, Zou Q, Shen Z. Artificial intelligence in pharmacovigilance: current applications and future prospects. Drug Saf. 2022;45(12):1317–1332.

[13]. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin PharmacolTher. 1981;30(2):239–245.
[14]. Meyboom RHB, Egberts ACG, Gribnau FWJ, et al. Causal or causal? The role of causality assessment in pharmacovigilance. Pharmacoepidemiol Drug Saf. 1997;6(S1):S51–S56.
[15]. Hennessy S, Strom BL. Real-world evidence: the devil is in the details. N Engl J Med. 2015;373(10):986–988.
[16]. Wang L, Rastegar-Mojarad M, Liu S. Clinical text mining in pharmacovigilance. Drug Saf. 2021;44(9):915–928.
[17]. Beam AL, Kohane IS. Big data and machine learning in healthcare. JAMA. 2018;319(13):1317–1318.
[18]. Coloma PM, Schuemie MJ, Trifirò G, et al. Combining EHRs and spontaneous reports for signal detection. Drug Saf. 2013;36(8):687–695.
[19]. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2020;43(12):1203–1219.
[20]. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019; 25:44–56.
[21]. Torrente-Rodríguez RM, et al. Wearable sensors for digital phenotyping and early disease detection. Nat Biomed Eng. 2021; 5:639–652.
[22]. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436.
[23]. European Medicines Agency. AI in Medicines Regulation: Reflection Paper. EMA; 2023.
[24]. Liu X, Rivera SC, Faes L, et al. Reporting guidelines for AI in healthcare. BMJ. 2020;368:m689.
[25]. Harpaz R, Vilar S, DuMouchel W. Data mining for pharmacovigilance signals. Clin PharmacolTher. 2012;91(6):1010–1021.
[26]. Food and Drug Administration. AI/ML-Based Software as a Medical Device Action Plan. FDA; 2024.
[27]. CIOMS. International Guidelines on Algorithm Transparency in PV. Geneva; 2022.
[28]. International Coalition of Medicines Regulatory Authorities (ICMRA). Global Principles for AI Governance in Medicines Regulation. 2023.
[29]. Senders JT, Arnaout O, Karhade AV, et al. Natural language processing in medicine. J Biomed Inform. 2020; 102:103–120.
[30]. Chapman WW, Nadkarni PM, Hirschman L, et al. NLP applications in clinical reporting. J Am Med Inform Assoc. 2011;18(5):544–551.
[31]. Denny JC, Collins FS. Precision medicine in 2030. N Engl J Med. 2021; 384:185–188.
[32]. Smuck M, Odonkor C, Wilt JK, Schmidt N, Swiernik M. Wearable sensor technology in health monitoring. NPJ Digit Med. 2021; 4:110.
[33]. Shin D, Park YJ, Lee J. AI-driven regulatory intelligence systems for PV. Drug Saf. 2023;46(2):115–128.
[34]. ajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019; 380:1347–1358.
[35]. Price WN, Gerke S, Cohen IG. Trustworthy AI in health care. Nat Med. 2021; 27:2076–2078.